The vascular endothelium produces numerous growth factors, cytokines, and bioactive mediators that critically regulate vascular homeostasis in health and disease. During the previous funding period, we provided evidence that expression of the transcription factor KLF2 in endothelial cells is induced by biomechanical stimuli such as laminar shear stress (LSS) and pharmacologic stimuli such as 3- hydroxyl-3-methyglutaryl coenzyme A reductase inhibitors (also known as statins). We also demonstrated that this induction of KLF2 by both stimuli was dependent on members of the MEF2 family of transcription factors. Studies aimed at elucidating KLF2 function in endothelial cell biology indicate that this factor directly regulates the expression of potent anti-inflammatory and anti-thrombotic factors such as thrombomodulin (TM) and endothelial nitric oxide synthase (eNOS). Importantly, evidence was also provided that the ability of laminar flow or statins to induce TM and eNOS was KLF2 dependent. Finally, our studies demonstrated that KLF2 can inhibit cytokine-mediated induction of pro- inflammatory and pro-thrombotic factors (e.g. tissue factor and plasminogen activator inhibitor-1) through its ability to reduce NF?B activity. Consistent with this effect, KLF2 overexpression increased blood-clotting time while knockdown of KLF2 reduced blood-clotting time. Taken together, these studies provide the basis for this renewal application that will explore the role of KLF2 in greater detail.
In Aim 1, we will explore the molecular basis for flow and statin-mediated induction of KLF2 in vitro and in vivo.
In Aim 2, we will determine the molecular basis of KLF2 mediated-induction of target genes and the functional consequences of KLF2 deficiency on vascular thrombosis in vivo. And finally, in Aim 3, we will determine the molecular basis of KLF2 mediated-inhibition of proinflammatory target genes and the functional consequences of KLF2-deficiency on atherothrombosis in vivo. We anticipate that these studies will provide novel and fundamental insights regarding the role of KLF2 in endothelial cell biology. Furthermore, a greater understanding of KLF2 function in the context of statins may provide the foundation for novel therapeutic strategies aimed at the treatment of vascular inflammatory and thrombotic disease states. Narrative: Despite maximal medical therapy, cardiovascular disease remains the number one cause of morbidity and mortality in our society. As such the identification of novel treatment strategies is clearly required. Current paradigms suggest that dysfunction of the vascular endothelial cell that lines all blood vessels is a critical early event in the pathogenesis of blood vessel diseases. Our studies have identified a genetic factor that can confer favorable properties to endothelial cells and is induced by a class of medications termed statins. Our efforts are focused on developing a greater understanding of this factors role in endothelial cells with the hope that such investigations may provide the foundation for novel therapeutic strategies aimed at the treatment of vascular inflammatory disease states.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-CVS-F (02))
Program Officer
Srinivas, Pothur R
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Case Western Reserve University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Date, Dipali; Das, Riku; Narla, Goutham et al. (2014) Kruppel-like transcription factor 6 regulates inflammatory macrophage polarization. J Biol Chem 289:10318-29
Shatat, Mohammad A; Tian, Hongmei; Zhang, Rongli et al. (2014) Endothelial Kruppel-like factor 4 modulates pulmonary arterial hypertension. Am J Respir Cell Mol Biol 50:647-53
Jain, Mukesh K; Sangwung, Panjamaporn; Hamik, Anne (2014) Regulation of an inflammatory disease: Kr├╝ppel-like factors and atherosclerosis. Arterioscler Thromb Vasc Biol 34:499-508
Nayak, Lalitha; Goduni, Lediana; Takami, Yoichi et al. (2013) Kruppel-like factor 2 is a transcriptional regulator of chronic and acute inflammation. Am J Pathol 182:1696-704
Adams, Gregory N; Stavrou, Evi X; Fang, Chao et al. (2013) Prolylcarboxypeptidase promotes angiogenesis and vascular repair. Blood 122:1522-31
Mahabeleshwar, Ganapati H; Qureshi, Muhammad Awais; Takami, Yoichi et al. (2012) A myeloid hypoxia-inducible factor 1*-Kruppel-like factor 2 pathway regulates gram-positive endotoxin-mediated sepsis. J Biol Chem 287:1448-57
Jeyaraj, Darwin; Haldar, Saptarsi M; Wan, Xiaoping et al. (2012) Circadian rhythms govern cardiac repolarization and arrhythmogenesis. Nature 483:96-9
Jeyaraj, Darwin; Scheer, Frank A J L; Ripperger, Jurgen A et al. (2012) Klf15 orchestrates circadian nitrogen homeostasis. Cell Metab 15:311-23
Adams, Gregory N; LaRusch, Gretchen A; Stavrou, Evi et al. (2011) Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis. Blood 117:3929-37
Atkins, G Brandon; Jain, Mukesh K; Hamik, Anne (2011) Endothelial differentiation: molecular mechanisms of specification and heterogeneity. Arterioscler Thromb Vasc Biol 31:1476-84

Showing the most recent 10 out of 42 publications